NCT06607809View on ClinicalTrials.gov

Inflammatory Markers (ICC, MCVL) and Nivolumab Response: Predicting Immunotherapy Success in Metastatic RCC

CompletedOBSERVATIONAL

Enrollment

99

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

January 1, 2023

Study Completion Date

January 1, 2024

Conditions

Metastatic Renal Cell Carcinoma

Trial Locations (1)

34865

Health Science University Kartal Dr. Lütfi Kirdar City Hospital, Istanbul

All Listed Sponsors

lead

Dr. Lutfi Kirdar Kartal Training and Research Hospital

OTHER_GOV